Treatment of acute myelogenous leukemia in adults with N4-behenoyl-1-β-D-arabinofuranosylcytosine
作者： Kiyoji Kimura , Ryuzo Ohno , Ichita Amaki , Kenichi Hattori , Yutaka Hirota
DOI: 10.1002/1097-0142(19851015)56:8<1913::AID-CNCR2820560803>3.0.CO;2-W
关键词:
摘要: Forty-five previously-untreated adult patients with acute myelogenous leukemia (AML) were treated N4-behenoyl-1-β-D-arabinofuranosyl-cytosine (BHAC) in a multi-institutional cooperative study. Among 41 evaluable patients, 15 (36.6%) achieved complete remission (CR) and 10 (24.4%) partial by daily administration of 3 to 8 mg/kg BHAC. Higher doses (5 or more) produced higher CR rates, all the observed among receiving total BHAC dosage 50 more period days more. The side effects mild acceptable: nausea–anorexia was 27% vomiting 17%. results this study thus indicate be effective for induction AML, deserve further clinical trials combination other anti-leukemic drugs. Cancer 56: 1913-1917, 1985.
sci-hub.se 参考文章(18)
Kazumasa Yamada, Kohei Kawashima, Yukio Kato, Yasuo Morishima, Mitsune Tanimoto, Ryuzo Ohno, Pharmacologic and Clinical Studies of N4-Behenoyl-1-Beta-D-Arabinofuranosylcytosine Recent results in cancer research. ,vol. 70, pp. 219- 229 ,(1980) , 10.1007/978-3-642-81392-4_23
W.A. Creasey, Studies on the metabolism of 5-iodo-2'-deoxycytidine in vitro. Purification of nucleoside deaminase from mouse kidney. Journal of Biological Chemistry. ,vol. 238, pp. 1772- 1776 ,(1963) , 10.1016/S0021-9258(18)81136-X
K. Kimura, K. Yamada, Y. Uzuka, T. Maekawa, F. Takaku, M. Shimoyama, M. Ogawa, I. Amaki, S. Osamura, M. Ito, Y. Sakai, M. Oguro, K. Hattori, A. Hoshino, Y. Hirota, K. Ohta, T. Nakamura, T. Masaoka, I. Kimura, M. Ichimaru, Phase I–II Study of N4-Behenoyl-1-β-D-Arabinofuranosylcytosine New Drugs in Cancer Chemotherapy. ,vol. 76, pp. 232- 240 ,(1981) , 10.1007/978-3-642-81565-2_19
Shigeru Tsukagoshi, Yoshio Sakurai, Hidehiko Kobayashi, Torao Ishida, Jun-ichi Oh-ishi, Michiko Aoshima, N4-Behenoyl-1-β-d-arabinofuranosylcytosine as a Potential New Antitumor Agent Cancer Research. ,vol. 37, pp. 2481- 2486 ,(1977)
Emil Frei, James S. Hewlett, Montague Lane, Robert W. Talley, John N. Bickers, William V. Leary, Dose Schedule and Antitumor Studies of Arabinosyl Cytosine (NSC 63878) Cancer Research. ,vol. 29, pp. 1325- 1332 ,(1969)
E. Colleen Moore, Seymour S. Cohen, Effects of Arabinonucleotides on Ribonucleotide Reduction by an Enzyme System from Rat Tumor Journal of Biological Chemistry. ,vol. 242, pp. 2116- 2118 ,(1967) , 10.1016/S0021-9258(18)96025-4
Shigeru Tsukagoshi, Yoshio Sakurai, Hidehiko Kobayashi, Torao Ishida, Jun-ichi Oh-ishi, Michiko Aoshima, Antitumor activities of newly synthesized N4-acyl-1-beta-D-arabinofuranosylcytosine. Cancer Research. ,vol. 36, pp. 2726- 2732 ,(1976)
AL Harris, C Potter, C Bunch, J Boutagy, DJ Harvey, DG Grahame-Smith, Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. British Journal of Clinical Pharmacology. ,vol. 8, pp. 219- 227 ,(1979) , 10.1111/J.1365-2125.1979.TB01005.X
Hugh L. Davis, jr., Donald B. Rochlin, Arthur J. Weiss, William L. Wilson, Neil C. Andrews, Robert Madden, Nell Sedransk, Cytosine Arabinoside (NSC 63878) Toxicity and Antitumor Activity in Human Solid Tumors Oncology. ,vol. 29, pp. 190- 200 ,(1974) , 10.1159/000224901
Edward S. Henderson, Introduction to the symposium on high-dose cytosine arabinoside. Medical and Pediatric Oncology. ,vol. 10, pp. 1- 3 ,(1982) , 10.1002/MPO.2950100703